Series B · Medtech & Devices · Dublin, Ireland · Founded 2016 · 26–35 employees
ProVerum Medical develops the ProVee System, a minimally invasive nitinol implant that gently reshapes the enlarged prostate to treat benign prostatic hyperplasia (BPH) in a doctor's office setting under local anesthesia. The Trinity College Dublin spin-out recently raised €68.6 million in Series B funding led by MVM Partners, bringing total funding to over €106 million since its 2016 founding. The company is currently conducting a 225-patient multi-center clinical trial and has filed device patents in Europe, US, Japan, and China. BPH affects an estimated 14 million men in the US and 20 million in Europe, representing a significant market opportunity for their innovative treatment alternative to traditional surgery.
No open roles listed right now.